Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study

#486

Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).

Aim(s): Here we report on outcomes in two placebo-treated patients from PROMID who received open-label O (30 mg IM q28d) after progression.

Materials and methods: Patient A was a woman aged 56 with a high hepatic tumor load at enrollment who progressed (liver) after five mo. Patient B was a woman aged 71 with multiple small hepatic lesions (hepatic tumor load <10%) at enrollment who progressed after six mo.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Rinke A,

Keywords: somatostatin analog, neuroendocrine, Octreotide, time to progression,